Recent Advances in Microbiota-Associated Metabolites in Heart Failure

被引:12
|
作者
Masenga, Sepiso K. [1 ,2 ]
Povia, Joreen P. [1 ]
Lwiindi, Propheria C. [1 ]
Kirabo, Annet [2 ]
机构
[1] Mulungushi Univ, Sch Med & Hlth Sci, HAND Res Grp, Livingstone Campus, Livingstone 10101, Zambia
[2] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA
基金
美国国家卫生研究院;
关键词
heart failure; microbiota; gut metabolites; hypertension; intestinal flora; bile acids; short chain fatty acids; branched chain amino acids; tryptophan; indole derivatives; TRIMETHYLAMINE-N-OXIDE; CHAIN FATTY-ACIDS; FACTOR-KAPPA-B; GUT MICROBIOTA; CARDIOVASCULAR-DISEASE; CARDIAC-HYPERTROPHY; OXIDATIVE STRESS; FECAL MICROBIOTA; GENE-EXPRESSION; AMINO-ACIDS;
D O I
10.3390/biomedicines11082313
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Heart failure is a risk factor for adverse events such as sudden cardiac arrest, liver and kidney failure and death. The gut microbiota and its metabolites are directly linked to the pathogenesis of heart failure. As emerging studies have increased in the literature on the role of specific gut microbiota metabolites in heart failure development, this review highlights and summarizes the current evidence and underlying mechanisms associated with the pathogenesis of heart failure. We found that gut microbiota-derived metabolites such as short chain fatty acids, bile acids, branched-chain amino acids, tryptophan and indole derivatives as well as trimethylamine-derived metabolite, trimethylamine N-oxide, play critical roles in promoting heart failure through various mechanisms. Mainly, they modulate complex signaling pathways such as nuclear factor kappa-light-chain-enhancer of activated B cells, Bcl-2 interacting protein 3, NLR Family Pyrin Domain Containing inflammasome, and Protein kinase RNA-like endoplasmic reticulum kinase. We have also highlighted the beneficial role of other gut metabolites in heart failure and other cardiovascular and metabolic diseases.
引用
收藏
页数:22
相关论文
共 50 条
  • [21] Recent advances in the management of chronic heart failure
    Haddad, Haissam
    Mielniczuk, Lisa
    Davies, Ross A.
    CURRENT OPINION IN CARDIOLOGY, 2012, 27 (02) : 161 - 168
  • [22] Recent advances in pharmacological treatment of heart failure
    Iacoviello, Massimo
    Palazzuoli, Alberto
    Gronda, Edoardo
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2021, 51 (11)
  • [23] RECENT ADVANCES IN TREATMENT OF HEART-FAILURE
    URBINAQUINTANA, A
    ACTA CIENTIFICA VENEZOLANA, 1978, 29 (03): : 185 - 190
  • [24] RECENT CONCEPTUAL ADVANCES IN CONGESTIVE HEART FAILURE
    GORLIN, R
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1962, 179 (06): : 441 - &
  • [25] Recent advances in the drug treatment of heart failure
    McAlister, FA
    Teo, KK
    POSTGRADUATE MEDICAL JOURNAL, 1998, 74 (877) : 658 - 661
  • [26] Pharmacological Treatment of Heart Failure: Recent Advances
    Chan, Jonathan C. H.
    Siddiqui, Areeb
    CURRENT CARDIOLOGY REVIEWS, 2024, 20 (02) : 29 - 38
  • [27] Recent advances in the management of chronic heart failure
    Krum, H
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 2000, 30 (04): : 475 - 482
  • [28] Recent Advances across the Spectrum of Heart Failure and Heart Transplant
    Masarone, Daniele
    Lombardi, Carlo
    Falco, Luigi
    Coscioni, Enrico
    Metra, Marco
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (05)
  • [29] The Role of Gut Microbiota and Its Metabolites in Patients with Heart Failure
    Cienkowski, Krzysztof
    Cienkowska, Alicja
    Kupczynska, Karolina
    Bielecka-Dabrowa, Agata
    BIOMEDICINES, 2024, 12 (04)
  • [30] Investigation of the bioactivation of glucoraphanin in human microbiota-associated mice
    Budnowski, J.
    Hanske, L.
    Iori, R.
    Loh, G.
    Blaut, M.
    ANNALS OF NUTRITION AND METABOLISM, 2011, 58 : 84 - 85